Andrew V. Biankin
A.O., B.Med.Sc., M.B.,B.S.(HONS), F.R.A.C.S., F.F.S.(R.C.P.A.), F.R.C.S.(Glasg), F.R.C.S.(Edin), Ph.D., F.R.S.E., F.Med.Sci.
RegiusProfessor of Surgery,
Director, Wolfson Wohl Cancer Research Centre, University of Glasgow
Chairman,Precision-Panc Therapeutic Development Platform
Executive Director, ICGC-ARGO, International Cancer Genome Consortium Accelerating Research in Genomic Oncology
Director, GPOL, Glasgow Precision Oncology Laboratory
Specialist Consultant in Precision Oncology and Therapeutic Development
Professor Andrew Biankin is the Regius Professor of Surgery at the University of Glasgow, a Cancer Research UK Clinician Scientist, a Wellcome Trust Senior Investigator, a Fellow of the Royal Society of Edinburgh and the Academy of Medical Sciences. He is the Director of the Wolfson Wohl Cancer Research Centre which is focused on precision oncology. He plays leadership roles in national and international consortia in cancer genomics and therapeutic development.
He has authored over 160 articles in major peer reviewed journals including seminal works on pancreatic cancer, precision medicine and the clinical management of pancreatic disease and sits on several international expert panels for pancreatic cancer. He is regarded as a key opinion leader and advises government agencies and international cancer organisations. He works closely with industry through appointments to advisory boards and is principal investigator on international clinical trials.
His work is currently focused on implementing Precision Oncology Practice in Health Systems internationally.